Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed

Minerva Gastroenterol (Torino). 2021 Dec;67(4):357-368. doi: 10.23736/S2724-5985.21.02907-7.

Abstract

In the last years, the gut microbiota achieved great importance, since several studies demonstrated its correlation with the immune system and with the maintenance of intestinal homeostasis, as well as with the regulation of the integrity of the epithelium and the intestinal motility. An imbalance in microbial species promotes a dysbiosis, which has been associated with chronic diseases such as metabolic syndrome, inflammatory diseases, and some behavior disorders. The association with gut microbiota and dysbiosis has been demonstrated mostly in inflammatory bowel disease (IBD). Several studies investigated the application of antibiotics, prebiotics, probiotics, and fecal microbiota transplantation in the treatment strategies for IBD. In this review, we discuss the recent findings on the potential role of the gut microbiota manipulation, with particular attention to bacterial microbiota, which could be implicated for a successful IBD therapeutic approach.

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • Dysbiosis
  • Fecal Microbiota Transplantation
  • Gastrointestinal Microbiome*
  • Humans
  • Inflammatory Bowel Diseases* / therapy